TMCI · Treace Medical Concepts, Inc. · Documents

Feb 27

Earnings call

Q4 2023 earnings call

Feb 27

Current report 8-K

Financial results, Regulation FD disclosure

Feb 27

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $187.12M ▲ 31.9% Net loss $49.53M Diluted EPS -$0.81

Jan 10

Current report 8-K Events of Jan 9

Regulation FD disclosure

Jan 8

Current report 8-K

Financial results

Nov 9

Earnings call

Q3 2023 earnings call

Nov 9

Current report 8-K

Financial results

Nov 9

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $40.76M ▲ 23.3% Net loss $17.52M Diluted EPS -$0.28

Aug 9

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $41.95M ▲ 40.0% Net loss $12.27M Diluted EPS -$0.20

Aug 8

Earnings call

Q2 2023 earnings call

Aug 8

Current report 8-K

Financial results

Jun 13

Current report 8-K Events of Jun 12

Completed an acquisition or sale of assets

Jun 1

Current report 8-K

Regulation FD disclosure, Other events

May 26

Current report 8-K Events of May 23

Shareholder vote results

May 9

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $42.2M ▲ 45.3% Net loss $13.45M Diluted EPS -$0.23

May 8

Earnings call

Q1 2023 earnings call

May 8

Current report 8-K

Financial results

Apr 4

Proxy statement DEF 14A Meeting May 23, 2023

Proxy statement

Apr 4

Annual report to holders ARS

Annual report to holders

Apr 4

Proxy statement DEFA14A

Proxy statement

Mar 10

Current report 8-K

Other events

Mar 8

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $141.84M ▲ 50.2% Net loss $42.82M Diluted EPS -$0.77

Mar 7

Earnings call

Q4 2022 earnings call

Mar 7

Current report 8-K

Financial results

Feb 23

Current report 8-K Events of Feb 16

Director or officer change, or executive pay

Feb 10

Current report 8-K

Entered into a material agreement, Other events

Feb 7

Registration statement S-3ASR

Registration statement

Jan 9

Current report 8-K

Financial results

Nov 9

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $33.06M ▲ 52.9% Net loss $12.13M Diluted EPS -$0.22

Nov 8

Earnings call

Q3 2022 earnings call

Nov 8

Current report 8-K

Financial results

Sep 28

Current report 8-K Events of Sep 27

Director or officer change, or executive pay

Aug 10

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Revenue $29.97M ▲ 45.1% Net loss $17.23M Diluted EPS -$0.31

Aug 9

Earnings call

Q2 2022 earnings call

Aug 9

Current report 8-K

Financial results

May 23

Current report 8-K Events of May 17

Shareholder vote results

May 6

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Revenue $29.05M ▲ 55.3% Net loss $9.04M

May 5

Earnings call

Q1 2022 earnings call

May 5

Current report 8-K

Financial results

May 4

Current report 8-K Events of Apr 29

Entered into a material agreement, Ended a material agreement, New debt or off-balance-sheet obligation

Apr 4

Proxy statement DEF 14A Meeting May 17, 2022

Proxy statement

Apr 4

Proxy statement DEFA14A

Proxy statement

Mar 4

Annual report 10-K FY2021, ended Dec 31

Annual report for FY2021

Revenue $94.42M ▲ 64.6% Net loss $20.55M

Mar 3

Current report 8-K

Financial results

Feb 25

Current report 8-K Events of Feb 22

Director or officer change, or executive pay

Jan 12

Earnings call

Q4 2021 earnings call

Jan 12

Current report 8-K Events of Jan 10

Financial results

Nov 4

Earnings call

Q3 2021 earnings call

Nov 4

Current report 8-K

Financial results

Nov 4

Quarterly report 10-Q FY2021 Q3, ended Sep 30

Quarterly report for FY2021 Q3

Revenue $21.62M ▲ 51.5% Net loss $6.42M